P
PathoQuest
PathoQuest is a biotechnology company identifying pathogens through High Throughput Sequencing (HTS).
About PathoQuest
PathoQuest operates in the biologics sector, providing genomic services that focus on pathogen detection to enhance clinical decision-making. The company serves clients in the pharmaceutical and biotechnology industries, particularly those involved in cell and gene therapy products. PathoQuest's business model revolves around offering specialized testing services that ensure the safety and efficacy of biological drugs. By obtaining Pharmaceutical Establishment status from the French ANSM, PathoQuest has solidified its position in the market, allowing it to conduct comprehensive biological drug testing activities. The company generates revenue through service contracts with biopharma companies, aiming to improve the safety of biologics and accelerate their time to market. PathoQuest's participation in industry events like BioProcess International Europe and BioPharma Asia webinars highlights its commitment to staying at the forefront of viral safety and pathogen detection advancements.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2010
- Headquarters
- Paris, France
- Employees
- 59
- Open positions
- 1
- Dealroom signal
- 72.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Sequencing, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Horizon Europe, observatoire industrial tech, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2026 | $0 | — | Charles River Laboratories International | ↗ |
| SERIES B✓Equity / VC | Nov 2021 | $17M | $66M | Turenne Capital · Eurazeo · SHS Capital · Verve Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for PathoQuest is 1K monthly website visits, down 37.5% over the last three months. PathoQuest's team declined 4.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Kurma Partners
Eurazeo
Aurinvest
Verve Ventures
Charles River Laboratories International
Norgine Ventures
SHS Capital
Turenne Capital
Other known investors3 additional known investors
Institut Pasteur
Fraser Finance- FFFraser Finance
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PathoQuest on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PathoQuest’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.